[go: up one dir, main page]

EA200700058A1 - Соединения, композиции и способы их использования - Google Patents

Соединения, композиции и способы их использования

Info

Publication number
EA200700058A1
EA200700058A1 EA200700058A EA200700058A EA200700058A1 EA 200700058 A1 EA200700058 A1 EA 200700058A1 EA 200700058 A EA200700058 A EA 200700058A EA 200700058 A EA200700058 A EA 200700058A EA 200700058 A1 EA200700058 A1 EA 200700058A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
compounds
methods
heart failure
sarcomere
Prior art date
Application number
EA200700058A
Other languages
English (en)
Other versions
EA016138B1 (ru
Inventor
Брэдли П. Морган
Алекс Муци
Пу-Пинг Лю
Эрика Крейнек
Тодд Тохимото
Дэвид Морганс
Original Assignee
Цитокинетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35785669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200700058(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Цитокинетикс, Инк. filed Critical Цитокинетикс, Инк.
Publication of EA200700058A1 publication Critical patent/EA200700058A1/ru
Publication of EA016138B1 publication Critical patent/EA016138B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)

Abstract

Некоторые замещенные производные соединения мочевины выборочно модулируют саркомер сердца, например, усиливая действие кардиального миозина, и полезны при лечении систолической сердечной недостаточности, включая конгестивную сердечную недостаточность.
EA200700058A 2004-06-17 2005-06-16 Соединения, фармацевтические композиции и способы лечения сердечной недостаточности EA016138B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58119704P 2004-06-17 2004-06-17
PCT/US2005/021100 WO2006009726A2 (en) 2004-06-17 2005-06-16 Substituted urea derivatives for treating cardiac diseases

Publications (2)

Publication Number Publication Date
EA200700058A1 true EA200700058A1 (ru) 2007-08-31
EA016138B1 EA016138B1 (ru) 2012-02-28

Family

ID=35785669

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700058A EA016138B1 (ru) 2004-06-17 2005-06-16 Соединения, фармацевтические композиции и способы лечения сердечной недостаточности

Country Status (32)

Country Link
US (12) US7507735B2 (ru)
EP (2) EP1765327B1 (ru)
JP (2) JP5080970B2 (ru)
KR (1) KR101276136B1 (ru)
CN (1) CN101035525A (ru)
AR (1) AR053405A1 (ru)
AU (1) AU2005264988B2 (ru)
BR (1) BRPI0512193B8 (ru)
CA (1) CA2570999C (ru)
CY (1) CY1115716T1 (ru)
DK (2) DK1765327T3 (ru)
EA (1) EA016138B1 (ru)
EC (1) ECSP077180A (ru)
ES (2) ES2522579T3 (ru)
HR (1) HRP20141048T1 (ru)
IL (1) IL180026A (ru)
MA (1) MA28738B1 (ru)
ME (1) ME01942B (ru)
MX (1) MXPA06014495A (ru)
MY (1) MY144470A (ru)
NO (1) NO340030B1 (ru)
NZ (1) NZ552404A (ru)
PE (1) PE20060438A1 (ru)
PL (2) PL1765327T3 (ru)
PT (1) PT1765327E (ru)
RS (1) RS53600B1 (ru)
RU (1) RU2410384C2 (ru)
SG (1) SG149027A1 (ru)
SI (1) SI1765327T1 (ru)
TW (1) TWI359812B (ru)
WO (1) WO2006009726A2 (ru)
ZA (1) ZA200700351B (ru)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495337B1 (en) * 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
MXPA05007513A (es) * 2003-01-14 2005-09-21 Cytokinetics Inc Compuestos, composiciones y metodos.
BRPI0512193B8 (pt) 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2006062982A2 (en) * 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
CA2589274A1 (en) * 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US20070208000A1 (en) * 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
JP5301284B2 (ja) * 2005-12-15 2013-09-25 サイトキネティクス・インコーポレーテッド 特定の化学物質、組成物および方法
EP1959947A2 (en) * 2005-12-15 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7718657B2 (en) * 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
EP1962852B1 (en) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
EP1973408A2 (en) * 2006-01-04 2008-10-01 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
KR20140031899A (ko) 2011-04-20 2014-03-13 더 리젠츠 오브 더 유니버시티 오브 미시건 최소의 각 의존성을 갖는 표시 장치들 및 이미징을 위한 스펙트럼 필터링
CN102288601B (zh) * 2011-05-16 2012-12-12 中国药科大学 一种肌球蛋白atp酶活性微量测定方法及其应用
AR091516A1 (es) * 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
US9709649B2 (en) * 2013-02-08 2017-07-18 Regents Of The University Of Minnesota System and method for assessing adenosine triphosphate hydrolysis rate using double saturation transfer magnetic resonance imaging and spectroscopy
US9895308B2 (en) 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
KR102474467B1 (ko) 2013-03-14 2022-12-05 암젠 인크 복소환식 화합물 및 그들의 용도
US9547107B2 (en) 2013-03-15 2017-01-17 The Regents Of The University Of Michigan Dye and pigment-free structural colors and angle-insensitive spectrum filters
WO2015142001A2 (ko) * 2014-03-21 2015-09-24 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
FI3247707T3 (fi) * 2015-01-22 2023-08-22 Myokardia Inc Sydänhäiriöiden kuten dilatoivan kardiomyopatian (dcm) hoitoon hyödyllisiä 4-metyylisulfonyylisubstituoituja piperidiiniureayhdisteitä
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
KR101766731B1 (ko) 2015-06-23 2017-08-10 충남대학교산학협력단 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法
TWI773657B (zh) 2015-12-18 2022-08-11 美商亞德利克斯公司 作爲非全身ｔｇｒ５促效劑之經取代之4-苯基吡啶化合物
US12084472B2 (en) 2015-12-18 2024-09-10 Ardelyx, Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists
KR20160108281A (ko) 2016-09-06 2016-09-19 충남대학교산학협력단 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물
HUE053603T2 (hu) * 2016-10-10 2021-07-28 Basf Se Katalizátor módosítása alkálifém, alkáliföldfém vagy ritkaföldfém ionokkal nitrovegyületek folytonos folyadék fázisú hidrogénezése során
US10256925B2 (en) * 2017-01-19 2019-04-09 Samsung Electronics Co., Ltd. Methods and wireless communication systems for wireless re-calibration of RF components of communication devices
CN110996953A (zh) 2017-06-30 2020-04-10 安进公司 用心脏肌小节激活剂治疗心力衰竭的方法
MX387531B (es) * 2017-06-30 2025-03-18 Amgen Inc Sintesis de omecamtiv mecarbil
JOP20200059A1 (ar) 2017-09-13 2020-03-12 Amgen Inc مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
US10836755B2 (en) * 2018-01-19 2020-11-17 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
US12187712B2 (en) 2018-06-26 2025-01-07 Cytokinetics, Inc. Cardiac sarcomere inhibitors
WO2020005887A1 (en) 2018-06-26 2020-01-02 Cytokinetics, Inc. Cardiac sarcomere inhibitors
EP3594199B1 (en) 2018-07-09 2020-07-01 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
SG11202101769YA (en) 2018-08-31 2021-03-30 Cytokinetics Inc Cardiac sarcomere inhibitors
EP4031541A1 (en) 2019-09-19 2022-07-27 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053175A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070124A1 (en) * 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
KR20230107282A (ko) 2020-11-12 2023-07-14 암젠 인크 오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
US11919909B2 (en) 2021-03-04 2024-03-05 Cytokinetics, Inc. Cardiac sarcomere inhibitors
KR20240006498A (ko) 2021-03-10 2024-01-15 암젠 인크 오메캄티브 메카빌의 합성
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US397782A (en) * 1889-02-12 Plunger water-closet
NL254871A (ru) 1959-08-14
US3939169A (en) * 1971-03-29 1976-02-17 Imperial Chemical Industries Limited Alkylene bis(pyridiniumareylene quaternary salts)
GB1339764A (en) * 1971-03-29 1973-12-05 Ici Ltd Pyridine derivatives
DE2942930A1 (de) 1979-10-24 1981-05-27 Basf Ag, 6700 Ludwigshafen Substituierte harnstoffe, deren herstellung und verwendung als herbizide
DE3271848D1 (en) 1981-12-03 1986-07-31 Basf Ag 1,3,5-triazinones, process for their preparation and their use in combating undesired plant growth
DE3147879A1 (de) 1981-12-03 1983-06-16 Basf Ag, 6700 Ludwigshafen 1,3,5-triazinone, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
AU2818584A (en) 1983-03-29 1984-10-25 Fmc Corporation N-phenyl-n-(pyridinyl-n-oxide)urea plant regulators
US4787931A (en) * 1984-03-06 1988-11-29 Fmc Corporation N-phenyl-N'-(pyridinyl-N-oxide)urea plant regulators
US4672066A (en) * 1985-04-22 1987-06-09 Hoffmann-La Roche Inc. Derivatives of 4-acetyl-3-hydroxy-2-alkyl-phenoxycarboxylic acids
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
GB9201180D0 (en) 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
WO1993024458A1 (en) * 1992-05-28 1993-12-09 Pfizer Inc. New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat)
ES2051647B1 (es) 1992-12-10 1995-01-16 Lipotec Sa Procedimiento para la preparacion de calcitonina de salmon.
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
EP0634402A1 (en) * 1993-07-14 1995-01-18 Takeda Chemical Industries, Ltd. Isochinolinone derivatives, their production and use
US5547966A (en) * 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
EP0784612A1 (en) 1994-10-04 1997-07-23 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
ES2218554T3 (es) * 1994-10-27 2004-11-16 Fujisawa Pharmaceutical Co., Ltd. Piridopirimidonas, quinolinas y n-heterociclos condensados que son antagonistas de bradiquinina.
US6010026A (en) 1994-11-22 2000-01-04 Aluminum Company Of America Assembly of aluminum can and threaded sleeve
US5556969A (en) * 1994-12-07 1996-09-17 Merck Sharp & Dohme Ltd. Benzodiazepine derivatives
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
GB9504361D0 (en) * 1995-03-04 1995-04-26 Glaxo Spa Heterocyclic compounds
GB9511355D0 (en) 1995-06-06 1995-08-02 Fujisawa Pharmaceutical Co Urea derivatives
US5972975A (en) * 1995-12-08 1999-10-26 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
DK0915859T3 (da) * 1996-07-23 2003-03-03 Neurogen Corp Visse substituerede benzylaminderivater; en ny klasse af Neuropeptid Y1-specifikke ligander
IT1284198B1 (it) 1996-07-30 1998-05-08 Beniamino Anzalone Carne vegetale
US6174905B1 (en) * 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
AUPO390996A0 (en) 1996-11-29 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives
JP2002241368A (ja) 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
WO1998041510A1 (fr) 1997-03-14 1998-09-24 Shionogi & Co., Ltd. Nouveaux derives du benzolactame et compositions medicamenteuses les contenant
WO1998050346A2 (en) 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
ATE399007T1 (de) 1997-05-23 2008-07-15 Bayer Pharmaceuticals Corp Raf kinase hemmer
ATE277612T1 (de) 1997-05-23 2004-10-15 Bayer Ag Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
DE69809967T2 (de) * 1997-11-05 2003-09-11 Choongwae Pharma Corp., Seoul/Soul Genipin-derivate mit einer die leber schützenden aktivität
ES2153809T3 (es) 1997-12-22 2005-07-16 Bayer Pharmaceuticals Corporation Inhibicion de la cinasa raf por uso de difnil-ureas sustituidas simetrica y asimetricamente.
PL205321B1 (pl) 1997-12-22 2010-04-30 Bayer Corp Zastosowanie podstawionych heterocyklicznych moczników do wytwarzania leku do hamowania kinazy raf, podstawione heterocykliczne moczniki oraz kompozycja farmaceutyczna je zawierająca
WO1999032463A1 (en) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
EP1041982B1 (en) 1997-12-22 2011-10-19 Bayer HealthCare LLC INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
JP4405602B2 (ja) 1998-04-16 2010-01-27 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト ヒストン脱アセチル化酵素阻害剤
US6329395B1 (en) * 1998-06-08 2001-12-11 Schering Corporation Neuropeptide Y5 receptor antagonists
HUP0103796A3 (en) 1998-06-08 2002-04-29 Schering Corp Neuropeptide y5 receptor antagonists and medicaments containing them
US6407124B1 (en) * 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
EP1104763A4 (en) 1998-08-11 2001-10-17 Sumitomo Pharma NAPHTHYRIDINE DERIVATIVES
US6331541B1 (en) 1998-12-18 2001-12-18 Soo S. Ko N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
JP2000256194A (ja) 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
JP2002534468A (ja) 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
WO2000052004A1 (en) * 1999-03-01 2000-09-08 The Regents Of The University Of California Thiacrown polymers for removal of mercury from waste streams
BR0009721A (pt) * 1999-04-15 2002-02-13 Bristol Myers Squibb Co Inibidores de tirosina quinase de proteìna cìclica
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
DE19921498A1 (de) * 1999-05-08 2000-11-16 Clariant Gmbh Verfahren zur Herstellung von wäßrigen Diazoniumsalzlösungen
DE60024830T2 (de) * 1999-07-09 2006-06-14 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
DE60024631T2 (de) 1999-07-26 2006-06-14 Banyu Pharma Co Ltd Biaryl-harnstoff-derivate
CA2385972A1 (en) 1999-10-01 2001-04-12 Haruhisa Ogita Novel diarylamide derivatives and use thereof as medicines
MXPA02004594A (es) 1999-11-16 2002-10-23 Boehringer Ingelheim Pharma Derivados de urea como agentes anti-inflamatorios.
HN2001000008A (es) * 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
JP2001278886A (ja) * 2000-03-28 2001-10-10 Dai Ichi Seiyaku Co Ltd ベンゾオキサジン誘導体及びこれを含有する医薬
US6495337B1 (en) 2000-03-29 2002-12-17 Cytokinetics, Inc. High throughput sarcomeric assay
CA2413274A1 (en) 2000-06-21 2001-12-27 George V. Delucca N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
GB0015601D0 (en) 2000-06-26 2000-08-16 Ferring Bv Novel antidiuretic agents
GB0015904D0 (en) 2000-06-28 2000-08-23 Hoffmann La Roche Inhibitors of HPV E1 helicase enzyme
US6573267B2 (en) * 2000-06-30 2003-06-03 Ortho-Mcneil Pharmaceutical, Inc. Useful aroyl aminoacyl pyrrole compounds
JP5079202B2 (ja) 2000-07-18 2012-11-21 大日本住友製薬株式会社 セロトニン再取り込み阻害剤
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US6645990B2 (en) * 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
US6573264B1 (en) 2000-10-23 2003-06-03 Cv Therapeutics, Inc. Heteroaryl alkyl piperazine derivatives
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
EP1360173A2 (en) * 2001-01-25 2003-11-12 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
JP2002220338A (ja) 2001-01-26 2002-08-09 Banyu Pharmaceut Co Ltd ビアリールウレア化合物又はその塩を有効成分として含有するＣｄｋ４及び／又はＣｄｋ６阻害剤
GB0117950D0 (en) * 2001-02-16 2001-09-19 Aventis Pharma Inc Novel heterocyclic urea derivatives andd their use as dopamine D3 receptor ligands
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
CA2443950C (en) 2001-04-20 2011-10-18 Bayer Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
JP2004530690A (ja) 2001-05-16 2004-10-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症性薬剤として有用なジアリールウレア誘導体
EP1395561A1 (en) * 2001-05-25 2004-03-10 Boehringer Ingelheim Pharmaceuticals Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
WO2002099388A2 (en) 2001-06-07 2002-12-12 Merck & Co., Inc. Benzodiazepine bradykinin antagonists
EP1408950B1 (en) * 2001-07-11 2007-04-25 Boehringer Ingelheim Pharmaceuticals Inc. Methods of treating cytokine mediated diseases
DE10134482A1 (de) 2001-07-16 2003-01-30 Bayer Ag Substituierte Isoindole und ihre Verwendung
AUPR688101A0 (en) 2001-08-08 2001-08-30 Luminis Pty Limited Protein domains and their ligands
US7297708B2 (en) 2001-09-06 2007-11-20 Bristol-Myers Squibb Company Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
US7361679B2 (en) 2001-09-12 2008-04-22 Kaken Pharmaceutical Co., Ltd. 2-phenyl-3-heteroarylpropionic acid derivative or salt thereof and medicine containing the same
US7320126B2 (en) * 2001-11-06 2008-01-15 Sandisk Corporation Implementation of in system programming to update firmware on memory cards
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003059258A2 (en) 2001-12-21 2003-07-24 Cytokinetics, Inc. Compositions and methods for treating heart failure
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2003062224A1 (en) 2002-01-17 2003-07-31 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
EP1472248A1 (en) 2002-01-17 2004-11-03 Eli Lilly And Company Modulators of acetylcholine receptors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
DE10208986A1 (de) 2002-02-28 2003-09-11 Aventis Pharma Gmbh Verwendung substituierter 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one zur Herstellung von Arzneimitteln mit hemmender Wirkung an der pankreatischen Lipase
JP4471262B2 (ja) 2002-03-07 2010-06-02 株式会社エス・ディー・エス バイオテック 置換イソキサゾールアルキルアミン誘導体及び農園芸用殺菌剤
AU2003240757B2 (en) 2002-03-28 2008-07-03 Merck Serono Sa Thiazolidine carboxamide derivatives as modulators of the prostaglandin F receptor
TW200400035A (en) 2002-03-28 2004-01-01 Glaxo Group Ltd Novel compounds
AU2003220935A1 (en) 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
US7105505B2 (en) * 2002-04-18 2006-09-12 Schering Corporation Benzimidazole derivatives useful as histamine H3 antagonists
AR040405A1 (es) 2002-04-18 2005-04-06 Schering Corp Derivados de bencimidazol utiles como antagonistas de histamina h3
WO2003091229A1 (en) 2002-04-23 2003-11-06 Bristol-Myers Squibb Company Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
AU2003229537A1 (en) 2002-05-17 2003-12-02 Lica Pharmaceuticals A/S Amino-functional chalcones
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
EP1777223A1 (en) * 2002-06-24 2007-04-25 Schering Corporation Indole derivatives useful as histamine H3 antagonists
EP2471533A1 (en) 2002-06-27 2012-07-04 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
HRP20050187A2 (hr) 2002-07-31 2005-10-31 Schering Aktiengesellschaft Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines
GB0218147D0 (en) 2002-08-05 2002-09-11 Oxford Glycosciences Uk Ltd Novel compounds
JP4606876B2 (ja) 2002-08-27 2011-01-05 キッセイ薬品工業株式会社 ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
DK1537116T3 (da) 2002-09-04 2010-09-27 Schering Corp Pyrazolopyrimidiner egnede til behandling af cancersygdomme
US6915814B2 (en) * 2002-09-04 2005-07-12 Dara Cheng Transparent pipe trap with means of enhancing the biodegradation of sink effluents
JP2006504690A (ja) 2002-09-10 2006-02-09 ファイザー・プロダクツ・インク Ｃｎｓ及びその他の障害の治療に有用なジアザ二環式化合物
ES2287542T3 (es) 2002-10-29 2007-12-16 L'oreal Composicion capilar que contiene un compuesto estirilpirazol.
MXPA05007513A (es) 2003-01-14 2005-09-21 Cytokinetics Inc Compuestos, composiciones y metodos.
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
US7531553B2 (en) * 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
AU2003902073A0 (en) * 2003-05-01 2003-05-15 Kevin Raymond Deguara A lighting substrate
ATE462432T1 (de) * 2003-05-05 2010-04-15 Probiodrug Ag Glutaminylcyclase-hemmer
US20070010529A1 (en) 2003-05-19 2007-01-11 Kanji Takahashi Nitrogenous heterocyclic compounds and medical use thereof
ATE366108T1 (de) * 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
GB0316915D0 (en) * 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US20080312192A1 (en) 2003-11-28 2008-12-18 Guido Bold Diaryl Urea Derivatives in the Treatment of Protein Kinase Dependent Diseases
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
BRPI0512193B8 (pt) * 2004-06-17 2021-05-25 Cytokinetics Inc composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso do composto ou sal
WO2006009729A2 (en) 2004-06-18 2006-01-26 Medtronic, Inc. Methods and devices for occlusion of an atrial appendage
US7176222B2 (en) * 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
WO2006089871A2 (en) 2005-02-23 2006-08-31 Neurosearch A/S Diphenylurea derivatives useful as erg channel openers for the treatment of cardiac arrhythmias
US7538223B2 (en) * 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
JP5301284B2 (ja) * 2005-12-15 2013-09-25 サイトキネティクス・インコーポレーテッド 特定の化学物質、組成物および方法
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
US7825120B2 (en) * 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
EP1959947A2 (en) * 2005-12-15 2008-08-27 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US7718657B2 (en) * 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
EP1962852B1 (en) * 2005-12-19 2017-01-25 Cytokinetics, Inc. Compounds, compositions and methods
US7672247B2 (en) * 2006-02-23 2010-03-02 International Business Machines Corporation Evaluating data processing system health using an I/O device
KR102474467B1 (ko) 2013-03-14 2022-12-05 암젠 인크 복소환식 화합물 및 그들의 용도
US9895308B2 (en) 2013-03-14 2018-02-20 Amgen Inc. Heterocyclic compounds and their uses
JP6858716B2 (ja) 2015-06-26 2021-04-14 アムジエン・インコーポレーテツド 心筋ミオシン活性化剤と洞房結節Ｉｆ電流阻害剤の併用療法
CN105572945B (zh) 2016-03-10 2019-06-14 京东方科技集团股份有限公司 阵列基板、偏光片贴附膜及其制备方法
MX387531B (es) 2017-06-30 2025-03-18 Amgen Inc Sintesis de omecamtiv mecarbil
EP3594199B1 (en) 2018-07-09 2020-07-01 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof
MA53226A (fr) 2018-08-17 2021-11-24 Amgen Inc Sel et formes cristallines d'omecamtiv mecarbil
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
CN115279349A (zh) 2020-02-10 2022-11-01 安进股份有限公司 奥美卡替莫卡必尔片剂
KR20230107282A (ko) 2020-11-12 2023-07-14 암젠 인크 오메캄티브 메카빌을 투여하여 심부전을 치료하는 방법
KR20240006498A (ko) 2021-03-10 2024-01-15 암젠 인크 오메캄티브 메카빌의 합성
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Also Published As

Publication number Publication date
CY1115716T1 (el) 2017-01-25
EP2862859A3 (en) 2015-05-06
US8513257B2 (en) 2013-08-20
RU2007101619A (ru) 2008-08-10
AU2005264988B2 (en) 2011-09-22
PE20060438A1 (es) 2006-07-01
CA2570999A1 (en) 2006-01-26
DK2862859T3 (en) 2018-08-13
NO20070257L (no) 2007-01-16
PL381801A1 (pl) 2007-07-09
EP1765327A4 (en) 2009-06-17
US20120172372A1 (en) 2012-07-05
US20060014761A1 (en) 2006-01-19
HK1101060A1 (en) 2007-10-05
AU2005264988A1 (en) 2006-01-26
HRP20141048T1 (hr) 2015-01-02
US20170267638A1 (en) 2017-09-21
TW200616996A (en) 2006-06-01
CA2570999C (en) 2014-01-07
JP5080970B2 (ja) 2012-11-21
US20090036447A1 (en) 2009-02-05
IL180026A (en) 2011-11-30
KR20070046070A (ko) 2007-05-02
TWI359812B (en) 2012-03-11
BRPI0512193B1 (pt) 2018-11-21
ES2686357T3 (es) 2018-10-17
EP1765327A2 (en) 2007-03-28
US20220185779A1 (en) 2022-06-16
US20190352267A1 (en) 2019-11-21
MXPA06014495A (es) 2007-03-01
US8110595B2 (en) 2012-02-07
MA28738B1 (fr) 2007-07-02
ECSP077180A (es) 2007-04-26
ME01942B (me) 2015-05-20
IL180026A0 (en) 2007-05-15
US10035770B2 (en) 2018-07-31
US10385023B2 (en) 2019-08-20
NZ552404A (en) 2010-04-30
RS53600B1 (en) 2015-02-27
NO340030B1 (no) 2017-02-27
US12264133B2 (en) 2025-04-01
PL216049B1 (pl) 2014-02-28
US20180305316A1 (en) 2018-10-25
PT1765327E (pt) 2014-11-24
SI1765327T1 (sl) 2014-12-31
US9150564B2 (en) 2015-10-06
EA016138B1 (ru) 2012-02-28
MY144470A (en) 2011-09-30
US20150005296A1 (en) 2015-01-01
HK1209729A1 (en) 2016-04-08
US9643925B2 (en) 2017-05-09
WO2006009726A2 (en) 2006-01-26
BRPI0512193A (pt) 2008-02-19
CN101035525A (zh) 2007-09-12
US20210198203A1 (en) 2021-07-01
US7507735B2 (en) 2009-03-24
EP2862859B1 (en) 2018-07-25
ZA200700351B (en) 2008-05-28
JP2012097093A (ja) 2012-05-24
AR053405A1 (es) 2007-05-09
EP1765327B1 (en) 2014-08-13
US8871769B2 (en) 2014-10-28
EP2862859A2 (en) 2015-04-22
DK1765327T3 (da) 2014-11-03
ES2522579T3 (es) 2014-11-17
JP2008503467A (ja) 2008-02-07
US10975034B2 (en) 2021-04-13
US20090099198A1 (en) 2009-04-16
RU2410384C2 (ru) 2011-01-27
US8101617B2 (en) 2012-01-24
US20140038983A1 (en) 2014-02-06
BRPI0512193B8 (pt) 2021-05-25
KR101276136B1 (ko) 2013-06-18
PL1765327T3 (pl) 2015-01-30
US20160115133A1 (en) 2016-04-28
SG149027A1 (en) 2009-01-29
WO2006009726A3 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
EA200700058A1 (ru) Соединения, композиции и способы их использования
MXPA05007513A (es) Compuestos, composiciones y metodos.
EP1605752A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
WO2007078815A3 (en) Certain chemical entities, compositions, and methods
WO2007089336A3 (en) Certain chemical entities, compositions and methods
WO2007070683A3 (en) Certain chemical entities, compositions and methods
WO2007078839A3 (en) Compounds, compositions and methods
WO2007070626A3 (en) Certain chemical entities, compositions and methods
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA201000558A1 (ru) Производные имидазола
EA201000550A1 (ru) Производные тиазола
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
DE602006016313D1 (de) Biphenylderivate und ihre verwendung bei der behandlung von hepatitis c
EA201000549A1 (ru) Производные пиперидина и пиперазина
EA200870116A1 (ru) Бициклические гетероарильные соединения
EA201100136A1 (ru) 2,4&#39;-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
ATE484508T1 (de) Furylverbindungen
ATE510822T1 (de) Kaliumkanalinhibitoren
WO2003059258A3 (en) Compositions and methods for treating heart failure
EA200702583A1 (ru) Использование фенилсемикарбазонов для обработки семян
EA201070281A1 (ru) Производные индол-2-она, двузамещенные в положении 3, их получение и их применение в терапии
ATE446753T1 (de) Verwendung von substituierten 2-thio-3,5-dicyano- 4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen
ATE549024T1 (de) Chinazolin-kaliumkanalhemmer
WO2003059265A3 (en) Compositions and methods for treating heart failure

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM RU